Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7411 to 7425 of 7707 results

  1. Multiple myeloma - bortezomib (consolidation therapy) [ID529]

    Discontinued [GID-TAG320]

    Technology appraisal guidance
    Discontinued

  2. Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (part review of TA697) [ID6335]

    In development [GID-TA11472] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Depatuxizumab mafodotin for treating recurrent EGFR-amplified glioblastoma [ID1244]

    Discontinued [GID-TA10242]

    Technology appraisal guidance
    Discontinued

  4. Evobrutinib for treating relapsing multiple sclerosis [ID6313]

    In development [GID-TA11357] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Vandetanib for treating metastatic, differentiated thyroid cancer refractory to or unsuitable for radioiodine therapy [ID907]

    Discontinued [GID-TA11259]

    Technology appraisal guidance
    Discontinued

  6. Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]

    Discontinued [GID-TAG321]

    Technology appraisal guidance
    Discontinued

  7. Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]

    Discontinued [GID-TAG300]

    Technology appraisal guidance
    Discontinued

  8. Lymphoma (non Hodgkin's) - bendamustine (with rituximab) [ID434]

    Discontinued [GID-TAG278]

    Technology appraisal guidance
    Discontinued

  9. Multiple sclerosis - sativex [ID387]

    Discontinued [GID-TAG368]

    Technology appraisal guidance
    Discontinued

  10. Ovarian (epithelial), fallopian, peritoneal cancer - paclitaxel (encapsulated in XR-17 [ID565]

    Discontinued [GID-TA11209]

    Technology appraisal guidance
    Discontinued

  11. Direct skeletal fixation of limb or digit prostheses using intraosseous transcutaneous implants (IPG270)

    This guidance has been updated and replaced by NICE interventional procedures guidance 795.

    Interventional procedures guidance
    Published
    23 July 2008

  12. EndoPredict gene expression profiling assay for assessing risk of breast cancer recurrence (MIB44)

    This advice has been updated and replaced by NICE diagnostics guidance 34.

    Medtech innovation briefing
    Published
    10 November 2015

  13. Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG641)

    This guidance has been updated and replaced by NICE interventional procedures guidance 737.

    Interventional procedures guidance
    Published
    30 January 2019

  14. Ab interno supraciliary microstent insertion with phacoemulsification for primary open-angle glaucoma (IPG605)

    October 2018: The device used in this procedure (CyPass) has been withdrawn by the manufacturer Alcon, because of concerns about its long-term safety. Further details can be found in the Voluntary Field Safety Notice issued by Alcon. Surgeons are advised not to implant this device, to return any unused devices to Alcon and to consider reviewing any patients who have already been implanted with CyPass. Therefore NICE has decided to withdraw its guidance. NICE would consider whether to issue new guidance on ab interno supraciliary microstent insertion with phacoemulsification for primary open-angle glaucoma should evidence using an appropriately CE marked device become available.

    Interventional procedures guidance
    Published
    28 February 2018

  15. Asthma: diagnosis, monitoring and chronic asthma management (NG80)

    This guideline has been updated and replaced by NICE guideline NG245.

    NICE guideline
    Last updated
    22 March 2021